Introduction {#S1}
============

The complexity of the highly aberrant cancer genomes seen in most human carcinomas has presented a formidable analytical challenge that has been the focus of recent efforts in genome-wide microarray profiling of gene expression and genomic copy number alterations (CNAs). However, such analyses performed independently face certain important limitations. Copy number profiling alone is best suited for the delineation of relatively focal high-amplitude events such as small high-level amplicons or narrow homozygous deletions; it provides few leads into larger regions of gains or loss that may span almost entire chromosome arms, changes commonly seen in human carcinomas. Expression profiling alone has provided fewer insights than expected into carcinomas with complex karyotypes because the gene expression changes contributed by passenger genes from regions of CNAs add considerable noise to these datasets. Finally, it is likely that there are certain patterns of CNAs (and associated gene expression changes) that cooperate with specific known (and unknown) mutations. Here, we harnessed the power of an integrated genomic approach to begin to reduce the complexity of lung adenocarcinoma and formulate new hypotheses regarding common cooperating events in this cancer.

The landmark discovery in 2004 that lung adenocarcinomas sensitive to the EGFR tyrosine kinase inhibitors contain somatic mutations in the *EGFR* kinase domain \[reviewed in ([@R31])\] represented a remarkable convergence of clinical observations and kinome sequencing efforts. However, many of the mutations described so far in lung adenocarcinomas may represent the "low-hanging fruit" and their cooperating genetic alterations remain largely unknown. It is likely that further advances in treating lung adenocarcinoma will require a deeper understanding of its biology and heterogeneity, beyond what is possible by individual genomic technologies. Although a number of studies have performed extensive DNA copy number profiling ([@R11]; [@R39]; [@R13]), gene expression profiling \[reviewed in ([@R19])\] or mutation screening ([@R5]; [@R17]) to characterize the lung adenocarcinoma genome, these individual approaches are reaching a point of diminishing returns, uncovering low prevalence mutations or amplifications but not clarifying the broader picture of how common mutations interact with common CNAs in this cancer.

We report an initial analysis of the largest integrated genomic dataset of lung adenocarcinoma assembled to date. We demonstrate how major mutated human lung cancer genes such as *EGFR* and *KRAS* appear as strong candidates without *a priori* knowledge, based on the integration of copy number and gene expression data. We further show how the integration of these data with mutational screening for all major known lung cancer genes leads to the identification of additional novel candidate lung cancer genes that may be targets of pathogenic mutations or CNAs. Specifically, we find that *EGFR* mutations in lung adenocarcinomas are strongly associated with low expression of *DUSP4* due to broad single copy losses at 8p. Dual-specificity phosphatases (DUSPs) are known to be transcriptionally up-regulated by mitogen-activated protein kinase (MAPK) signaling as a negative feedback mechanism ([@R25]) and DUSPs and other negative regulators of kinase signaling are emerging as putative tumor suppressors in other cancers ([@R8]; [@R32]).

Results {#S2}
=======

Patterns of mutations in lung adenocarcinomas {#S3}
---------------------------------------------

Frozen samples of 199 primary lung adenocarcinomas from 199 patients were processed for genomic analyses (See [Supplementary Materials and Methods](#SD1){ref-type="supplementary-material"}). Basic clinical and pathologic data are summarized in [Supplementary Table 1](#SD4){ref-type="supplementary-material"}. We used a variety of approaches including Sanger sequencing, mutation-specific PCR assays, and mass-spectrometry-based genotyping, to profile the mutational status of established somatic lung cancer genes, including *EGFR, KRAS, BRAF, ERBB2, PIK3CA, LKB1, PTEN*, and *TP53* (see [Supplementary Materials and Methods](#SD1){ref-type="supplementary-material"}). Mutations in at least one of these genes were detected in 140/199 cases (70%) ([Figure 1A](#F1){ref-type="fig"}). Mutations in *EGFR, KRAS, ERBB2*, or *BRAF*, present collectively in 98/199 cases (49%), were completely mutually exclusive, as expected from published data. Mutations in *EGFR* and *LKB1* may also be largely mutually exclusive, with only 1/43 *EGFR*-mutant tumors also showing a mutation in *LKB1*, compared with 27/156 *EGFR*-wild type tumors (p=0.012). Mutations in *TP53* were frequent (27%) and commonly occurred with other mutations. Few cases showed mutations in *PTEN* (4%) or *PIK3CA* (2%), in line with prior studies ([@R28]; [@R17]).

Recurrent genomic copy number alterations {#S4}
-----------------------------------------

Array-based comparative genomic hybridization (aCGH) was performed using Agilent 44k arrays. Frequent gains were seen on chromosome arms 1q, 5p, 7p, 8q, 12q, and 14q, and frequent losses on 3p, 6q, 8p, 9p, 13q, and 17p ([Figure 1B](#F1){ref-type="fig"}). These major CNAs are consistent with those reported in other lung adenocarcinoma datasets ([@R11]; [@R39]). We focus below on 8p losses, one of the most common broad CNAs in lung adenocarcinoma, occurring in approximately ¼ of cases. We also identified focal, recurrent, high-amplitude CNAs defined heuristically as minimal common regions (MCR) of amplification or deletion (see [Supplementary Materials and Methods](#SD1){ref-type="supplementary-material"}), several of which contain well-described oncogenes or tumor suppressor genes that may be driving the selection for these CNAs ([Supplementary Table 2](#SD4){ref-type="supplementary-material"}). For instance, focal high level amplification at 14q13 centered on *TITF1*, recently recognized in approximately 12% of lung adenocarcinomas ([@R11]; [@R39]), was also revealed here. Other MCRs may define new cancer genes and we list the boundaries of these intervals and propose genes of interest within them ([Supplementary Table 2](#SD4){ref-type="supplementary-material"}).

Non-random patterns of CNAs associated with *EGFR/KRAS* mutations and survival {#S5}
------------------------------------------------------------------------------

Simple aCGH recurrence plots fail to convey associations between genomic CNAs and hence are not useful in defining distinct pathways of lung adenocarcinoma pathogenesis. We therefore applied an unsupervised clustering algorithm based on non-negative matrix factorization (NMF) to extract recurrent associations between CNAs (see Methods). An analysis of cluster membership ([Supplementary Figure 1](#SD4){ref-type="supplementary-material"}) showed stable assignments to two or three clusters suggesting the existence of up to three distinct patterns of CNAs within the lung adenocarcinomas in this set. These clusters are shown in aggregate in [Figure 2](#F2){ref-type="fig"} (and with case-by-case data in Supplemental Figures 2 and 3). Analysis of the two-cluster classification (clusters designated kA and kB) revealed that the kA subgroup, containing about 60% of cases, was distinguished by 1q and 8q gains as well as losses at 5q and 16q. The remaining cases were in the kB subgroup and were characterized by gains of 7p (containing *EGFR*) and 12q (containing *MDM2*), and losses at 8p and 10q. In the three-cluster classification (clusters k1-3 respectively), the k2 cluster, similar to the kA cluster, was defined by gains of 1q and 8q. The k3 cluster, similar to the kB cluster, was defined by gains of 7p and 12q. A third cluster, k1, was marked by losses at 5q and 16q and gains at 5p and 14q (containing *TITF1*).

To complement the above analysis, we also examined, in a simple pair-wise fashion, six of the CNA associations highlighted by the NMF clustering. This confirmed that many of the associations were statistically significant per moderate copy number thresholds (see Methods). These included associations between *EGFR*-containing 7p11.2 gains and 8p losses (p=0.007), gains of 1q and 8q (p=0.009), gains of 7p and 12q (p=0.004), losses at 8p and 10q (p\<0.001), and gains at 5p and 14q (p=0.02). Except for the latter ([@R13]), none of these associations have been noted previously. The co-occurrence of 7p gains and 10q losses was not significant.

The unsupervised clustering of the CNA data also showed a strong correlation with *EGFR* and *KRAS* mutation status ([Supplementary Table 3](#SD4){ref-type="supplementary-material"}). In both the two-cluster and the three-cluster classifications, *EGFR* mutant tumors were distributed in a highly non-random fashion, with most falling into the kB or k3 cluster, respectively (both p\<0.0001), while *KRAS*-mutant tumors were enriched in the kA and k2 clusters (respectively, p=0.0004 and p\<0.0001).

Finally, Kaplan-Meier survival analysis of these NMF clusters showed a significant survival advantage for patients whose tumors were in the *EGFR*-mutant-rich kB cluster in the 2-cluster separation (p=0.006) ([Figure 3](#F3){ref-type="fig"}). In the 3-cluster separation, the *EGFR*-mutant-rich k3 cluster showed a survival advantage over the k1 cluster (p=0.03) while patients within the *KRAS*-mutant-rich k2 cluster were in an intermediate group for clinical outcome. For comparison, Kaplan-Meier survival analysis based on *EGFR* mutation status alone did not detect statistically significant differences in the present dataset ([Supplementary Figure 4](#SD4){ref-type="supplementary-material"}). Overall, these analyses indicate that the genetic heterogeneity of lung adenocarcinoma is not random and that coordinated genomic alterations may reflect underlying distinct oncogenic pathways with different clinical outcomes.

Associations between CNAs and expression profiles {#S6}
-------------------------------------------------

As genomic gains are expected to alter the expression of biologically relevant genes, we examined the mRNA expression profiles (based on Affymetrix U133A array hybridizations) of cases defining MCRs of gain in order to identify copy-number driven gene expression changes within or surrounding these MCRs ([Supplementary Table 4](#SD4){ref-type="supplementary-material"}). As expected, the expression profile of cases defining the MCR of gain at 7p11.2 demonstrated highly significant over-expression of *EGFR*. Similarly, *KRAS* was significantly over-expressed in cases defining the MCR of gain at 12p12. Likewise, the expression profile of cases defining the MCR of gain at 12q14 demonstrated significant over-expression of *MDM2*. For cases defining the MCR of gain at 5p15, *SKP2* ([@R40]), was significantly over-expressed, while *TERT* was not. The overexpression of *SKP2* (at 5p13) reflects the fact that samples used to delineate MCRs individually have, by definition, broader regions of gain that overlap the MCR. As for *TERT*, other strong candidate genes within certain MCRs were not found to be significantly over-expressed by transcriptomic analysis, including *MYC* on 8q24 and *TITF1* on 14q13 ([@R39]; [@R36]; [@R11]). It should be emphasized, however, that some transcripts may not be adequately measured by microarrays for technical or biological reasons and therefore these data cannot be used in isolation to exclude driver genes. Finally, the analysis of genes significantly over-expressed in cases defining the MCR of gain at 8q24 highlighted *COPS5*, previously shown to drive selection for 8q amplicons along with *MYC* ([@R2]).

Associations between genomic copy number losses and gene expression profiles were considerably less robust, yielding few if any significant genes in comparable analyses of samples with either 9p21 or 19p13 losses (results not shown). This may be due to the narrower range of expression values seen in the context of genomic losses compared to gene amplifications.

Associations between genomic gains and activating mutations at specific genes {#S7}
-----------------------------------------------------------------------------

*EGFR* expression at the mRNA level correlated well with gene copy number by aCGH, as shown in an integrated representation of expression, copy number, and mutation data ([Supplementary Figure 5](#SD4){ref-type="supplementary-material"}). This analysis also reveals that *EGFR*-mutation is associated with generally higher levels of *EGFR* expression among both *EGFR*-amplified and non-amplified cases ([Supplementary Figure 5](#SD4){ref-type="supplementary-material"}). A similar analysis of the 12p12 MCR and *KRAS* mutation status demonstrated a trend for cases defining the MCR to harbor a *KRAS* mutation, but this did not reach statistical significance (not shown). We did not detect any relationship between *LKB1* mutations and (single copy) deletions at 19p13; this may either reflect the less reliable detection of single copy losses compared to multiple copy gains in the midst of admixed non-neoplastic cells, or the reported finding that mutations and deletions at *LKB1* generally do not co-occur ([@R10]). There was no evidence of genomic loss at *PTEN* in the 8 *PTEN*-mutant tumors. Finally, among associations between mutations and unrelated loci, we also found a significant co-occurrence of *EGFR* mutations and p16/*CDKN2A* deletions (p=0.007), that largely reflects their mutual association with 8p losses, as described below. This finding is also consistent with the reported loss of p14ARF expression in *EGFR*-mutant lung cancers ([@R21]).

Associations between expression profiles and mutations {#S8}
------------------------------------------------------

Supervised analyses of Affymetrix U133A expression profiles based on *EGFR, KRAS*, and *p53* mutation status were performed ([Table 1](#T1){ref-type="table"}, [Supplementary Table 5](#SD4){ref-type="supplementary-material"}). The other five mutated genes (*BRAF, ERBB2, PIK3CA, LKB1, PTEN*) did not yield robust profiles, but these analyses lacked power given the lower numbers of samples with mutations in these genes. Notably, the number of significantly differentially expressed genes in *EGFR*-mutant cases was much greater than in *KRAS*-mutant cases (probe sets significant at FDR \<5%: 2571 and 103, respectively). This observation is all the more striking given the marginally stronger statistical power of the *KRAS* analysis (48 *KRAS* mutants vs only 43 *EGFR* mutants). This suggests either that the impact of *KRAS* mutation on gene expression is less distinctive than that of *EGFR* mutation, or that *EGFR* mutations arise in a more restricted and homogeneous cell type than *KRAS* mutations, or that there is biological or etiologic heterogeneity among *KRAS*-mutant tumors ([@R27]). The more distinctive expression profile of *EGFR*-mutant cases was also supported by an unsupervised clustering analysis ([Supplementary Figure 6](#SD4){ref-type="supplementary-material"}). We limit ourselves here to three notable observations. First, both the *EGFR* and *KRAS* lists contain the respective mutated genes, as measured by multiple probe sets, at or near the top ([Table 1](#T1){ref-type="table"}), presumably reflecting a consistent level of expression required for their oncogenic effect plus their amplification in a subset of cases. Secondly, we noted that different members of the DUSP family of MAP kinase phosphatases, known to be transcriptionally induced by MAPK signaling to provide negative feedback regulation of the same, are highly differentially expressed in *EGFR*- and *KRAS*-mutant tumors ([Table 1](#T1){ref-type="table"}). In the latter tumors, *DUSP6* was relatively over-expressed, consistent with its previous description in other *KRAS*-mutant signatures ([@R34]), as was *DUSP4* ([Supplementary Table 5](#SD4){ref-type="supplementary-material"}). In contrast, *DUSP4* was the single most highly significantly [under]{.ul}-expressed gene in *EGFR*-mutant tumors, an unexpected finding given that it is normally up-regulated by MAPK signaling ([@R25]). We follow up this observation further below. The third observation emerging from these two lists is the over-representation of genes from specific chromosomal regions, notably under-expressed genes from 8p (including *DUSP4*) on the *EGFR*-mutant list and over-expressed genes from 1q on the *KRAS*-mutant list ([Table 1](#T1){ref-type="table"}). These reflect the non-random associations of 8p loss and 1q gain with *EGFR* and *KRAS* mutations, respectively (see above). Finally, the expression profile of *p53* mutation was also robust but its discussion is beyond the scope of this report ([Supplementary Table 5](#SD4){ref-type="supplementary-material"}).

Loss of *DUSP4* at 8p in *EGFR* mutant tumors {#S9}
---------------------------------------------

As demonstrated above, *DUSP4*, a dual specificity MAP kinase phosphatase (a.k.a. *MKP-2*), was almost uniformly under-expressed in *EGFR* mutated cases relative to lung adenocarcinomas lacking *EGFR* mutations ([Table 1](#T1){ref-type="table"}). A more detailed comparison of *DUSP4* transcript levels showed that expression was significantly lower in *EGFR*-mutant lung adenocarcinomas than in normal lung, *KRAS*-mutant tumors, and tumors lacking both mutations ([Figure 4A](#F4){ref-type="fig"}). A substantial proportion of *EGFR* mutant tumors demonstrated single copy genomic loss at 8p12 that included *DUSP4*. This proportion ranged from 35% to 67% of *EGFR*-mutant cases depending on the stringency of the sample-specific thresholds used to consider *DUSP4* deleted. Conversely, a substantial proportion of *DUSP4*-deleted tumors contained *EGFR* mutations, ranging from 41% to 56%, again depending on the aforementioned stringency. Regardless of the threshold used to score deletions, the association of *DUSP4* genomic loss and *EGFR* mutations was highly significant (p\<0.0001).

Integration of gene expression with copy number and *EGFR* mutation status showed that, while low *DUSP4* transcript levels correlated well with *DUSP4* genomic loss, this relationship was most evident among *EGFR*-mutant tumors ([Figure 4B](#F4){ref-type="fig"}). We also confirmed by dual-color fluorescence *in situ* hybridization the co-occurrence of *DUSP4* single-copy loss and *EGFR* amplification in the same tumor cells in *EGFR*-mutant cases that had both findings by aCGH ([Figure 4C](#F4){ref-type="fig"}). Notably, *DUSP4* does not reside in a narrow MCR of loss and therefore would not have emerged as a strong candidate based on algorithms using copy number data alone, but is the top candidate based on the expression profile of *EGFR* mutant tumors ([Table 1](#T1){ref-type="table"}), highlighting the value of an integrated genomics approach. Finally, we also screened *DUSP4* for somatic mutations. A total of 101 lung adenocarcinoma samples (99 tumor DNAs and cell lines H1299 and H522) were sequenced but no somatic mutations of *DUSP4* were identified.

Given the significant co-occurrence of *EGFR* mutations and p16/*CDKN2A* deletions (p=0.007) described above, we examined their relationship with *DUSP4* deletions. This showed that p16/*CDKN2A* deletions and *DUSP4* deletions are strongly correlated (p=0.0001) ([Supplementary Figure 7](#SD4){ref-type="supplementary-material"}). Indeed, among *DUSP4*-diploid tumors, *EGFR* mutations and p16/*CDKN2A* deletions were not associated, indicating that their co-occurrence is largely secondary to their mutual association with *DUSP4* deletions.

A distinct clinical subset of lung adenocarcinoma defined by *DUSP4* loss {#S10}
-------------------------------------------------------------------------

Patients with tumors harboring *DUSP4* deletion had a better overall survival than patients whose tumors did not show this alteration (p=0.042 for difference between survival curves; p=0.031 from univariate Cox proportional hazards regression; hazard ratio of 2.06) ([Figure 4D](#F4){ref-type="fig"}). Although *DUSP4* loss associates with *EGFR* mutations, it is notable that *EGFR* mutation status alone had only a sub-significant effect on overall survival in the present set of patients (p=0.18 for difference between survival curves; p=0.159 from univariate Cox proportional hazards regression; hazard ratio of 1.66) ([Supplementary Figure 4](#SD4){ref-type="supplementary-material"}).

Preferential suppression of EGFR-mutant lung adenocarcinoma growth by DUSP4 {#S11}
---------------------------------------------------------------------------

This candidacy of *DUSP4* as the prime driver gene for 8p loss in *EGFR* mutant tumors is biologically plausible given its known transcriptional up-regulation by, and negative feedback regulation of, MAPK signaling ([@R25]). By microarray analysis, *DUSP4* expression is decreased following inhibition of mutant EGFR in the H1975 lung adenocarcinoma cell line ([@R12]). We have also found that DUSP4 is transcriptionally up-regulated by mutant EGFR signaling in HBECs ([Supplementary Figure 8](#SD4){ref-type="supplementary-material"}). Thus, we hypothesized that the oncogenicity of mutant EGFR may be enhanced by loss or attenuation of the negative autoregulatory loop normally provided by DUSP4. We therefore examined the impact of DUSP4 on the growth of lung adenocarcinoma cells. First, we used RNA interference by short interfering RNAs (siRNA) to study the effects of reducing DUSP4 levels in 6 lung adenocarcinoma cell lines with available data on *DUSP4* genomic copy number \[data from ref. ([@R9]); Affymetrix SNP array data, K. Michel & R. Thomas, unpublished; Agilent 244K aCGH data, J. Bean & W. Pao, unpublished\] and *DUSP4* transcript levels relative to HBECs ([Figure 5A](#F5){ref-type="fig"}). In the 3 lung adenocarcinoma cell lines with moderate to high *DUSP4* expression, all diploid for 8p, namely PC9, HCC827, and H358, *DUSP4* knockdown enhanced growth significantly at 48 hours ([Figure 5A](#F5){ref-type="fig"}). In contrast, in the 3 lung adenocarcinoma cell lines with already low *DUSP4* expression, associated in 2/3 lines with 8p single copy deletion (H1650 and H3255), *DUSP4* knockdown had essentially no effect. To confirm these findings in an isogenic background, we examined the effect of *DUSP4* knockdown in HBECs with or without EGFR L858R ([Figure 5B](#F5){ref-type="fig"}). This showed that reducing DUSP4 levels enhances growth in the presence of EGFR L858R but not in the parental line.

Next, we examined the growth effects of re-expressing or increasing the level of DUSP4 by transfection with a DUSP4-GFP expression plasmid. The expression and appropriate subcellular localization of the fusion protein were confirmed respectively by western blotting using a GFP antibody ([Supplementary Figure 9A](#SD4){ref-type="supplementary-material"}) and fluorescence microscopy, the latter showing the expected nuclear localization of DUSP4 ([Supplementary Figure 9B](#SD4){ref-type="supplementary-material"}). In H1650 and H3255, both characterized by *EGFR* mutation, 8p loss (J. Bean & W. Pao, unpublished data), and low *DUSP4* expression, as well as in H358, a *KRAS*-mutant lung adenocarcinoma line with moderate *DUSP4* expression, transient transfection with the DUSP4-GFP expression plasmid resulted in a significant reduction in growth ([Figure 5C](#F5){ref-type="fig"}). Interestingly, attempts to derive corresponding stable transfectants (in H1650) were unsuccessful because of loss of GFP-positive cells after one week of antibiotic selection in the DUSP4-GFP-transfected cultures (but not in the GFP-transfected ones) ([Supplementary Figure 10](#SD4){ref-type="supplementary-material"}), an observation consistent with the growth inhibition observed in the above transient transfection experiments. Similar difficulties in isolating stable DUSP4 cDNA transfectants have been observed in other settings ([@R38]). Overall, these data provide functional validation of the growth suppressive effects of DUSP4 in lung adenocarcinoma lines with activating mutations of kinase signaling pathways.

Discussion {#S12}
==========

Several levels of data here support the link between *DUSP4* loss and *EGFR*-mutant tumors. Our analysis of the aCGH data showed that lung adenocarcinomas display non-random patterns of co-occurring gains and losses, one of which is characterized by 7p gains (including the *EGFR* locus) and 8p losses. These tumors frequently showed *EGFR* mutation (p\<10^-4^), which is not unexpected as mutant *EGFR* alleles are known to undergo selective amplification ([@R35]). However, the 8p losses were broad and MCR analysis did not yield a candidate sub-region on this chromosome arm. Previous studies of lung cancers have noted 8p losses, but also failed to narrow the putative target region ([@R39]). Allelic losses on 8p are well described in other carcinomas, including breast, prostate, and bladder, with most studies finding a complex pattern that cannot be reduced to a single minimally deleted region \[reviewed in ([@R1])\]. Notably, *DUSP4* has also been proposed as a driver of 8p losses in breast cancer ([@R4]). Our integrated genomics strategy showed that *DUSP4*, at 8p12, was the most consistently under-expressed gene in *EGFR* mutant cases compared to *EGFR* wild type cases (nominal p\<10^-9^, two-sided stratified Wilcoxon). By aCGH, using a moderate stringency threshold, the *DUSP4* region showed evidence of single-copy genomic loss in approximately 24% of lung adenocarcinomas, including approximately 45% of *EGFR* mutant cases (p\<10^-4^), while the latter accounted for only 21% of cases in our dataset. No somatic mutations in *DUSP4* were detected, suggesting haploinsuffiency as the basic alteration, an oncogenic mechanism recently illustrated by *RPS14* loss in the 5q- myelodysplastic syndrome ([@R7]). We also show that re-expression of DUSP4 in EGFR-mutant lung adenocarcinoma lines with 8p loss and low endogenous DUSP4 results in reduced growth, and conversely, knockdown of DUSP4 in cell lines with high DUSP4 leads to enhanced growth. Since DUSPs are known to be transcriptionally up-regulated by MAPK signaling as a negative feedback mechanism, the data support the hypothesis that *DUSP4* loss cooperates with *EGFR* mutation to allow full oncogenic activation of the MAPK pathway. Clinically, *DUSP4* loss has a significant impact on overall survival, further supporting its biological significance in lung adenocarcinoma.

MAPK pathway activation by signaling through growth factor receptors is modulated by negative feedback inhibition at the receptor ([@R23]), at the level of RAS (e.g. by sprouty proteins) ([@R32]), and at the level of *ERK* (by DUSPs). *DUSP4* functions in the nucleus to dephosphorylate and thereby inactivate the *ERK, JNK*, and *p38* MAP kinases ([@R25]). In addition to its role in regulating MAPK-mediated mitogenic signals, *DUSP4* has also been implicated in the control of replicative senescence and of p53-mediated apoptosis ([@R38]; [@R33]). *DUSP4* is among several DUSPs well-described as transcriptional targets of MAPK signaling ([@R30]; [@R3]). Suppression of mutant EGFR signaling in the H1975 lung adenocarcinoma cell line causes down-regulation of *DUSP4* ([@R12]). More broadly, there is a growing recognition that disruption of negative feedback control of MAPK signaling is an important component of oncogenic kinase signaling ([@R3]). Finally, our finding that *EGFR* mutations and *p16/CDKN2A* deletions are linked through their mutual association with *DUSP4* losses suggests that the deregulated mitogenic signaling that occurs in the context of combined *DUSP4* loss and EGFR mutation (or possibly other mutations activating the MAPK pathway) may drive selection for loss of the locus encoding p16CDKN2A and p14ARF, known mediators of senescence or apoptosis in response to inappropriate mitogenic signals ([@R15]; [@R20]). This recalls the relationship between *p16CDKN2A* deletions and BRAF and EGFR mutants in melanoma and glioma, respectively ([@R20]; [@R24]). Finally, as mutant EGFR and p16 bypass together fail to fully transform HBECs ([@R29]), the addition of DUSP4 knockdown to such experiments will be of interest.

Although the association of *EGFR* mutation status with *DUSP4* genomic loss and under-expression was striking, the genomic losses on 8p were consistently broad, suggesting the possibility of more than one driver gene. We note two other regions of interest on 8p, the *TNFRSF10* TRAIL receptor gene cluster at 8p21.3, similarly implicated by our data on the basis of decreased expression in *EGFR*-mutant tumors ([Table 1](#T1){ref-type="table"}) and previously proposed as a tumor suppressor locus in lung cancers ([@R14]), and a slightly more telomeric gene on 8p21.3, *DOK2*, encoding an adaptor protein that suppresses KRAS activation. Evidence for *DOK2* as another lung adenocarcinoma tumor suppressor on 8p, based on a mouse knockout model that leads to the development of lung adenocarcinomas and also in part on the present integrated dataset, is presented elsewhere ([@R22]). All 27 stringently detected *DUSP4*-deleted tumors (including the 15 *EGFR*-mutant cases) also showed loss of the *TNFRSF10* gene cluster and *DOK2*. Five additional cases showed losses of these two gene loci without *DUSP4* deletion; interestingly, none of these 5 samples showed *EGFR* mutations and 4 were instead *KRAS*-mutant. This difference between *DUSP4/DOK2*-codeleted and *DOK2*-deleted/*DUSP4*-intact cases was significant (p=0.046), suggesting that lung adenocarcinomas harbor two types of 8p deletions, with those that extend more centromerically to include *DUSP4* being more strongly associated with *EGFR* mutations. Indeed, a mapping of 8p losses in relation to *EGFR* or *KRAS* mutation status strengthens the notion of mutation type-specific patterns of 8p loss ([Figure 6](#F6){ref-type="fig"}). The observation that 8p losses in lung adenocarcinomas are consistently broad may reflect a selective advantage provided by the reduced function of more than one gene (here two different negative regulators of kinase signaling), a multiple driver gene model that may also hold for other regions of broad gains or losses.

Several other previously unrecognized or underappreciated associations emerged from this integrated genomic analysis. We found a significant inverse relationship between mutations in *EGFR* and *LKB1*, strengthening observations from others ([@R18]; [@R6]). LKB1 cooperates with mutant KRAS in mouse lung tumorigenesis ([@R10]). Other associations that may point to distinct oncogenic pathways include coamplification of 1q21-23 and 8q24 (including *MYC*) (p=0.009), and coordinate gains at 5p15 (including *TERT*) and 14q13 (including *TITF1*) (p=0.02).

We have described here an initial analysis of the largest integrated genomic study of lung adenocarcinoma assembled to date. The identification of DUSP4 as a novel growth suppressor in lung adenocarcinoma exemplifies the type of emergent observation made possible by the integration of multiple levels of genomic data in large, well annotated datasets. The present associations between mutation status, copy number changes and expression data strengthen the notion that there exist at least 2 or 3 distinct, recurrent oncogenic pathways that drive lung adenocarcinoma. Similar insights are now emerging in other cancers based on the systematic integration of multiple levels of genomic data ([@R37]; [@R26]).

Methods {#S13}
=======

See [Supplementary information](#SD1){ref-type="supplementary-material"} for complete methods.
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![**A**. Survey of major known mutations in 199 lung adenocarcinomas. *EGFR, KRAS, BRAF*, and *ERBB2* mutations are mutually exclusive. Mutant samples (columns) are sorted by grouped mutations per one-way average-linkage hierarchical clustering on binary data. Black represents samples with single mutations, while red are samples harboring mutations in more than one gene. Sample numbers are indicated at left, 140 cases harbored at least one mutation. Samples without detected mutations in these genes are not shown. **B**. Recurrent genomic copy number alterations in 199 lung adenocarcinomas. Frequency of gain (red) and loss (blue) is shown by genomic position across the 22 autosomes. Centromeres are identified by dotted vertical lines; acrocentric p-arms and loci lacking array coverage are indicated as gaps. The most prevalent losses are at 8p and 9p21; among gains, 1q, 5p, and 8q are most frequent.](nihms-108311-f0001){#F1}

![Unsupervised clustering of genomic copy number data in 199 lung adenocarcinomas. The NMF method was used to generate K=2 and K=3 clustering, both of which showed stable cluster assignments whereas clustering into more than 3 groups did not yield stable clusters ([Supplementary Figure 1](#SD4){ref-type="supplementary-material"}). Red is gain and green is loss with the color intensity indicating the level of copy number change; white is no change. Selected notable gains and losses defining individual clusters are indicated. Approximate proportions made up by each cluster are shown as percentages. The two-cluster classification shows that the kA subgroup (n=118) is notable for 1q and 8q gains. The kB subgroup (n=81) is characterized by gains of 7p and 12q, and losses at 8p and 10q. In the three-cluster classification, the k2 cluster (n=64) was similar to the kA cluster (arrow), being defined by gains of 1q and 8q. The k3 cluster (n=65) was similar to the kB cluster (arrow), showing gains of 7p and 12q. The additional cluster k1 (n=70) was marked by gains at 5p and 14q.](nihms-108311-f0002){#F2}

![Impact of aCGH cluster assignment on overall survival. Kaplan-Meier survival showed a survival advantage for patients whose tumors were in the *EGFR*-mutant-rich kB cluster (designated B) in the 2-cluster separation (p=0.006). In the 3-cluster separation, the *EGFR*-mutant-rich k3 cluster (designated C) showed a survival advantage over the k1 cluster (designated A) (p=0.03). Outcome differences between the *KRAS*-mutant-rich k2 cluster (designated B) and the other two clusters were not statistically significant.](nihms-108311-f0003){#F3}

![**A**. Comparison of *DUSP4* levels in normal non-neoplastic lung tissue samples, and lung adenocarcinomas with different *EGFR* and *KRAS* mutation status. *DUSP4* expression is significantly lower in *EGFR*-mutant lung adenocarcinomas than in normal lung tissue or other subsets of lung adenocarcinoma. P-values are from two-sided Wilcoxon test. **B**. *DUSP4* copy number versus expression, annotated for *EGFR* mutation status. Samples with alterations are as indicated in the legend. The correlation of copy number to expression for the *DUSP4* locus is highly significant (p\<0.0001 and R=0.43, Pearson\'s product moment correlation). *EGFR* mutant samples generally had lower *DUSP4* expression for a given *DUSP4* copy number, compared to samples lacking *EGFR* mutation. **C**. [*DUSP4* / *EGFR* dual color FISH]{.ul}. *DUSP4* signals are red, *EGFR* in green. Arrows indicate the single *DUSP4* signal in each nucleus; there are multiple *EGFR* signals per nucleus in this *EGFR*-mutant lung adenocarcinoma. **D**. *DUSP4* loss defines a favorable clinical subset of lung adenocarcinoma. The p=0.042 for difference between survival curves; p=0.031 from univariate Cox proportional hazards regression; hazard ratio of 2.06 (95% confidence interval: 1.02-4.20). Data are from 198 samples with complete data for both variables.](nihms-108311-f0004){#F4}

![**A**. *DUSP4* knockdown enhances growth of lung adenocarcinoma cell lines. In 3/3 cell lines with moderate to high *DUSP4* expression, *DUSP4* knockdown by two different siRNAs (D1, D2) resulted in growth enhancement (all p\<0.05 except H1975) relative to control siRNA (C). In contrast, in 3/3 *EGFR*-mutant cell lines with low baseline *DUSP4* expression, *DUSP4* knockdown had no significant effect. For comparison, *EGFR* knockdown reduced the growth of 4/5 *EGFR*-mutant lines. *EGFR* knockdown did not suppress growth of the *KRAS*-mutant H358 line. Thymidine incorporation was measured 48-72 hours after transfection. DUSP4 expression was measured by Q-RT-PCR, normalized to TBP expression and expressed as the ratio of the cell line expression to that of HBECs. **B**. *DUSP4* knockdown preferentially enhances growth of human bronchial epithelial cells (HBEC) in the presence of mutant EGFR. To confirm the findings shown in A. in an isogenic background, we examined the effect of DUSP4 knockdown in HBECs stably transfected with *EGFR* L858R. Reducing *DUSP4* levels (using D1 siRNA as in A.) enhances growth compared to control siRNA (C) in the presence of *EGFR* L858R (p\<0.05) but not in the parental line (thymidine incorporation measured 48-72 hours after transfection). *DUSP4* knockdown was confirmed by RT-PCR as shown in the adjacent agarose gel image. **C**. DUSP4 cDNA transfection inhibits cell growth of lung adenocarcinoma cell lines. Thymidine incorporation was measured 24 hours after *DUSP4* cDNA transfection. Transfection efficiencies, estimated by FACS analysis of GFP-positive cells after 24 hours of transfection, were 54-60% for H1650 cells, 20-44% for H3255 cells, and 46% for H358 cells. V: vector-transfected cells; D: DUSP4-GFP cDNA transfected cells. For all three figure parts, significant differences relative to control are shown by asterisks if p\<0.05 (\*) or p\<0.01 (\*\*) (t-test, 2 tails, equal variance analysis).](nihms-108311-f0005){#F5}

![[8p losses stratified by mutation group]{.ul}. The frequency of deletion on 8p in the region from 20 to 32 megabases (blue, left-axis) is plotted by chromosomal position, along with the position and direction of transcription for three gene loci of interest: *DUSP4, DOK2*, and the *TNF* receptor cluster. The frequency of mutation in *EGFR* and *KRAS* (right-axis) is plotted by chromosome 8p position, for samples showing 8p losses at a given point in 8p. This highlights the higher frequency of *EGFR* mutations among cases with 8p losses overall and shows that this association is strongest in a region encompassing *DUSP4*. In contrast, *KRAS* mutations are less common in 8p-deleted cases and when present, appear to preferentially affect cases whose 8p losses include *DOK2* and the *TNF* receptor cluster.](nihms-108311-f0006){#F6}

###### 

*EGFR* and *KRAS* expression profiles. Top 25 genes shown; complete lists provided in [Supplementary Table 5](#SD4){ref-type="supplementary-material"}.

  Genes differentially expressed in *EGFR* mutant versus wild type tumors   Genes differentially expressed in *KRAS* mutant versus wild type tumors                                                          
  ------------------------------------------------------------------------- ------------------------------------------------------------------------- ------ --------- -------------- --------------- ------ ---------
  *DUSP4*\*                                                                 8p12-p11                                                                  -6.7   2.4E-11   *MCL1*\*       1q21            5.1    3.3E-07
  *EGFR*\*                                                                  7p12                                                                      6.4    1.4E-10   *IGF2BP3*\*    7p11            -5.0   5.2E-07
  *PRDM4*\*                                                                 12q23-q24.1                                                               -6.4   1.8E-10   *KRAS*\*       12p12.1         5.0    7.1E-07
  *TXNRD1*                                                                  12q23-q24.1                                                               -6.0   1.5E-09   *PRNPIP*       1p32            -4.9   8.0E-07
  *GTF2E2*                                                                  8p21-p12                                                                  -6.0   1.6E-09   *FTSJ2*        7p22            -4.9   8.3E-07
  *GPR177*                                                                  1p31.3                                                                    6.0    1.8E-09   *SNRPD3*       22q11.23        -4.8   2.0E-06
  *MGC13098*\*                                                              7p13                                                                      6.0    2.0E-09   *KIAA1033*     12q24.11        4.7    2.8E-06
  *GALNT10*\*                                                               5q33.2                                                                    5.9    3.5E-09   *RHOB*         2p24            4.7    2.9E-06
  *LRRC31*                                                                  3q26.2                                                                    5.8    5.0E-09   *MED18*        1p35.3          -4.6   3.6E-06
  *KIAA0319L*                                                               1p34.2                                                                    5.8    7.9E-09   PAC 886K2      1p36.11         -4.5   7.3E-06
  *MKL2*                                                                    16p13.12                                                                  5.8    8.8E-09   *LANCL2*       7q31.1-q31.33   -4.5   8.1E-06
  *RAD51L1*                                                                 14q23-q24.2                                                               5.7    1.2E-08   *USP2*         11q23.3         -4.5   8.4E-06
  *KIAA0495*                                                                1p36.32                                                                   5.7    1.3E-08   *FOXRED2*      22q12.3         -4.4   1.3E-05
  *RHCE*                                                                    1p36.11                                                                   5.7    1.4E-08   *RPL13A*       19q13.3         4.3    1.5E-05
  *HIP1*                                                                    7q11.23                                                                   5.6    1.7E-08   *SMPDL3A*      6q22.31         4.3    1.6E-05
  *GPR172B*                                                                 17p13.2                                                                   5.6    2.2E-08   *STK24*        13q31.2-q32.3   4.3    1.6E-05
  *TNFRSF10B*                                                               8p22-p21                                                                  -5.6   2.5E-08   *MAFF*         22q13.1         4.3    1.7E-05
  *C16orf58*\*                                                              16p11.2                                                                   5.5    3.2E-08   *NXPH4*        12q13.3         -4.3   1.8E-05
  *RNF40*                                                                   16p11.2-p11.1                                                             5.5    3.2E-08   *C7orf30*      7p15.3          -4.3   2.0E-05
  *MYST1*                                                                   16p11.2                                                                   5.5    4.0E-08   *LOC81691*     16p12.2         -4.3   2.0E-05
  *ADCY9*                                                                   16p13.3                                                                   5.4    6.1E-08   *SNHG3-RCC1*   1p36.1          -4.3   2.0E-05
  *LRRC47*                                                                  1p36.32                                                                   5.4    6.8E-08   *TRMT5*        14q23.1         -4.3   2.0E-05
  *KYNU*                                                                    2q22.2                                                                    -5.4   7.5E-08   *PPIE*         1p32            -4.2   2.1E-05
  *RFK*                                                                     9q21.13                                                                   -5.4   8.2E-08   *IVNS1ABP*     1q25.1-q31.1    4.2    2.2E-05
  *HLA-DMA*                                                                 6p21.3                                                                    5.3    9.7E-08   *DUSP6*        12q22-q23       4.2    2.3E-05

Note: for genes that were represented on these lists of the top 25 genes by more than one Affymetrix probe set (indicated by \*), only the top scoring probe set is shown; SWS = stratified Wilcoxon statistic with the sign of the statistic indicating either over- or under-expression; two-sided p-values calculated from a normal distribution; PAC886K2 indicates genomic clone containing EST corresponding to Affymetrix probe set 213685_at.
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